Key Takeaways
- • Golden Triangle leasing activity reached 151,182 sq ft in Q2 2026, with London recording 73,027 sq ft—more than triple Q1 figures—accounting for nearly half of regional take-up and signaling strong demand rotation across London, Oxford, and Cambridge markets.
- • UK life sciences venture capital funding hit a record £3.06bn across 231 deals in H1 2026, representing 65% growth versus H1 2025, with Q2 deal volumes accelerating to £2.31bn—206% higher quarter-on-quarter and 29% above the previous quarterly record.
- • AI-related take-up in London surged to 751,162 sq ft in H1 2026, up from 197,258 sq ft in the same period in 2025, reflecting broad expansion in science and technology demand beyond traditional life sciences sectors.
- • Isomorphic Labs' £1.55bn Series B funding round accounted for 67% of all Q2 capital raised, demonstrating concentration in AI-enabled drug discovery as the primary driver of the quarter's exceptional funding growth.
- • Cambridge and Oxford combined for 290,834 sq ft of lettings across 18 deals in H1 2026, representing 75.4% of Golden Triangle activity and reflecting record Q1 leasing in Cambridge followed by strong Q2 performance in London.
Summary
The Golden Triangle markets of London, Oxford, and Cambridge demonstrated record leasing momentum in H1 2026, driven by sustained venture capital investment in life sciences and AI-enabled technologies. According to Knight Frank, total leasing activity across the three markets reached 151,182 sq ft in Q2, led by a dramatic acceleration in London, which recorded 73,027 sq ft—more than triple the Q1 figure and representing nearly half of Golden Triangle take-up. The performance reflects continued demand rotation between the three core markets, following record leasing activity in Cambridge during Q1.
Venture capital funding emerged as the primary catalyst for real estate demand. UK life sciences venture capital investment reached £3.06bn across 231 deals in H1 2026, marking a 65% increase compared to the same period in 2025. The funding surge was particularly pronounced in Q2, when deal volumes accelerated sharply to £2.31bn—representing a 206% quarter-on-quarter increase and 299% year-on-year growth. This Q2 figure also exceeded the previous quarterly record by 29%, indicating exceptional momentum. Much of the growth derived from a smaller number of larger transactions, particularly in AI-enabled drug discovery, with Isomorphic Labs' £1.55bn Series B funding round accounting for 67% of all capital raised in Q2.
Beyond traditional life sciences lettings, London recorded 751,162 sq ft of AI-related take-up during H1 2026, surging from 197,258 sq ft in H1 2025. The quarter's largest London transaction involved robotics company Humanoid, which leased 40,000 sq ft of lab-enabled space at One Triton Square. Cambridge and Oxford combined for 290,834 sq ft of lettings across 18 deals in H1 2026, accounting for 75.4% of Golden Triangle activity. Knight Frank attributed London's strong performance to broader expansion in science and technology demand, signaling institutional confidence in the region's innovation ecosystem alongside elevated venture funding availability.
Venture capital funding emerged as the primary catalyst for real estate demand. UK life sciences venture capital investment reached £3.06bn across 231 deals in H1 2026, marking a 65% increase compared to the same period in 2025. The funding surge was particularly pronounced in Q2, when deal volumes accelerated sharply to £2.31bn—representing a 206% quarter-on-quarter increase and 299% year-on-year growth. This Q2 figure also exceeded the previous quarterly record by 29%, indicating exceptional momentum. Much of the growth derived from a smaller number of larger transactions, particularly in AI-enabled drug discovery, with Isomorphic Labs' £1.55bn Series B funding round accounting for 67% of all capital raised in Q2.
Beyond traditional life sciences lettings, London recorded 751,162 sq ft of AI-related take-up during H1 2026, surging from 197,258 sq ft in H1 2025. The quarter's largest London transaction involved robotics company Humanoid, which leased 40,000 sq ft of lab-enabled space at One Triton Square. Cambridge and Oxford combined for 290,834 sq ft of lettings across 18 deals in H1 2026, accounting for 75.4% of Golden Triangle activity. Knight Frank attributed London's strong performance to broader expansion in science and technology demand, signaling institutional confidence in the region's innovation ecosystem alongside elevated venture funding availability.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.